GlaxoSmithKline could file up to 20 new drugs for regulatory approval before 2020 as it seeks to revitalize a portfolio hit by falling sales of best-selling inhaled lung treatment Advair, the company said on Tuesday.
Seven of them may reach the market before the end of decade, it added.
{iframe}http://www.reuters.com/article/2015/11/03/us-gsk-r-d-idUSKCN0SS1B320151103{/iframe}